论文部分内容阅读
ALK~+弥漫大B细胞淋巴瘤(ALK~+DLBCL)是淋巴瘤中一种罕见的和具有明显差异性的病理类型,2008年WHO将其归类为DLBCL一个独特的亚型,该病侵袭性高,容易复发,目前尚无规范有效的治疗方案。采取多学科协作体系(MDT)有利于制定规范化、个体化的治疗方案,探索针对ALK~+DLBCL患者更有效的治疗方法,从而
ALK ~ + diffuse large B cell lymphoma (ALK ~ + DLBCL) is a rare and significantly different pathological type in lymphoma. In 2008, WHO classified it as a unique subtype of DLBCL. High, easy to relapse, there is no standardized and effective treatment options. Adopting a multidisciplinary collaboration system (MDT) is conducive to the development of standardized and individualized treatment plans and to exploring more effective treatments for patients with ALK ~ + DLBCL